CANDEL THERAPEUTICS, INC. CADL 深 滬
等待開盤 10-08 09:30:00 美东时间
5.63
+0.160
+2.93%
華盛通- 最 高5.73
- 今 開5.48
- 成交量 58.07万股
- 最 低 5.405
- 昨 收 5.47
- 總市值 3.09亿
- 52周最高 14.60
- 市盈率 靜 --
- 換手率 1.06%
- 52周最低 3.785
- 委 比 -7.73%
- 總股本 5489.51万
- 歷史最高 14.78
- 量 比 0.83
- 振 幅 5.94%
- 歷史最低 0.66
- 每 手 1
- 風險率 3.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Candel Therapeutics to Present at the SITC 2025 Annual Meeting
Candel Therapeutics will present data from its enLIGHTEN™ Discovery Platform and CAN-2409 program in NSCLC at the SITC Annual Meeting. Dr. Paul Peter Tak will discuss positive phase 3 results for CAN-2409 in prostate cancer. Researchers will present on the multimodal immunotherapy approach and immune responses in NSCLC, highlighting improved survival in ICI-refractory patients. CAN-2409 has received multiple FDA designations, including Regenerati...
10-03 13:05
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
Candel Therapeutics Announces CAN-2409 Significantly Improves Disease-Free Survival In Prostate Cancer, Showing Benefit Across Radiation Modalities In Phase 3 Trial
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent of the specific modality of radiation therapy usedNEEDHAM, Mass., Sept.
09-29 20:20
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Candel Therapeutics will present CAN-2409 Phase 3 trial data for intermediate-to-high-risk localized prostate cancer at ASTRO 2025. The oral presentation, featuring Glen Gejerman, MD, MBA, highlights CAN-2409's combination with external beam radiation. The abstract was selected for ASTRO’s Science Highlights. CAN-2409 has received multiple FDA designations, including Fast Track and Orphan Drug, and demonstrated positive results in phase 2a trials...
09-17 12:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pelthos Therapeutics (AMEX:PTHS) stock increased by 25.9% to $28.27 du...
09-04 01:06
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
Candel Therapeutics appoints Carl H. June, M.D., a pioneer in CAR-T cell therapy, to its Research Advisory Board. His expertise will support the advancement of its viral immunotherapy candidates, CAN-2409 and CAN-3110, across multiple solid tumors. CAN-2409 has shown promising results in phase 2a and 3 trials, with Fast Track and Orphan Drug Designations. Dr. June’s加入 brings significant expertise in immunology and T cell engineering to the compan...
09-02 12:05
Candel Therapeutics to Participate in Upcoming Investor Conferences in September
Candel Therapeutics announced that its CEO, Paul Peter Tak, will participate in several investor conferences in September 2025, including Citigroup's Biopharma Back to School Conference in Boston, the Cantor Global Healthcare Conference in New York, and the H.C. Wainwright Global Investment Conference in New York. Each event will feature live webcasts accessible via the company's website. Candel, a clinical-stage biopharmaceutical company, focuse...
08-28 12:05
Candel Therapeutics Extends Lease Agreement in Needham
Candel Therapeutics ( ($CADL) ) has issued an announcement. On August 18, 2025,...
08-22 05:01
Candel Therapeutics Advances with Promising Cancer Therapies
Candel Therapeutics, Inc. ( ($CADL) ) has released its Q2 earnings. Here is a b...
08-19 12:09
